Agree.
The Board are accomplished, but they needed some modern, up-to-date expertise in the Biotech space.
Dr. Charmaine Gittleson is fresh from the coalface as CMO of a $115B biotech gorilla.
Needless to say her clinical, regulatory and commercial achievements at CSL dwarfs Diamond and Nuket's experience in getting a drug approved.
In her own words:
"Under my oversight of the clinical group the company had an unprecedented run of five major product approvals and launches within a 24-month period."
Rockstar recruitment - well played Moses and Goolsbee!
.
Ann: Antisense Therapeutics appoints new Non-Executive Director, page-19
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.9¢ |
Change
-0.046(34.1%) |
Mkt cap ! $80.23M | |||
| Open | High | Low | Value | Volume |
| 8.7¢ | 9.0¢ | 8.6¢ | $2.082M | 23.82M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 250808 | 8.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.9¢ | 312804 | 3 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |